Investor Centre

A drug discovered and developed in Australia has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of cystic fibrosis: one of the world’s most common life-shortening genetic diseases.

Bronchitol® (mannitol) is the first of a new class of cystic fibrosis medicines designed to tackle one of the fundamental problems that leads to loss of lung function.  It has been the subject of one of the largest clinical trial programs undertaken in cystic fibrosis - conducted in over 600 patients in 10 countries around the world and co-ordinated by scientists based in Australia.